Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory

Vitiligo: Mechanisms of Pathogenesis and Treatment

(2020) Michael L. Frisoli et al.   Annual Review of Immunology

Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade

(2020) Shinsuke Nakao et al.   Science Translational Medicine

Cellular cytotoxicity is a form of immunogenic cell death

(2020) Luna Minute et al.   Journal for ImmunoTherapy of Cancer

Broad Antibody and Cellular Immune Response from a Phase 2 Clinical Trial with a Novel Multivalent Poxvirus Based RSV Vaccine

(2020) Elke Jordan et al.   JOURNAL OF INFECTIOUS DISEASES

Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?

(2019) Maria Eugenia Davola et al.   OncoImmunology

Lymph node conduits transport virions for rapid T cell activation

(2019) Glennys V. Reynoso et al.   NATURE IMMUNOLOGY

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

A Phase 1 Dose Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

(2019) Margaret E Gatti-Mays et al.   CLINICAL CANCER RESEARCH

Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343

(2019) Marlon J Hinner et al.   CLINICAL CANCER RESEARCH

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

(2019) Xinyue Qi et al.   Nature Communications

Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

(2019) Stefanie K. Wculek et al.   Journal for ImmunoTherapy of Cancer

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

(2019) Christina Claus et al.   Science Translational Medicine

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

(2019) Phillip R. Pittman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

(2019) José Medina-Echeverz et al.   Nature Communications

Transposable element expression in tumors is associated with immune infiltration and increased antigenicity

(2019) Yu Kong et al.   Nature Communications

Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines

(2018) Stephen J. Russell et al.   CANCER CELL

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway

(2018) Todd Bartkowiak et al.   CLINICAL CANCER RESEARCH

T Cells in Nonlymphoid Tissues Give Rise to Lymph-Node-Resident Memory T Cells

(2018) Lalit K. Beura et al.   IMMUNITY

The function and dysfunction of memory CD8+ T cells in tumor immunity

(2018) James L. Reading et al.   IMMUNOLOGICAL REVIEWS

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

(2018) Edgar Turner Overton et al.   PLoS One

Human endogenous retroviruses and their implication for immunotherapeutics of cancer

(2018) A S Attermann et al.   ANNALS OF ONCOLOGY

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

(2018) Simone L. Park et al.   NATURE

Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung

(2017) A C Zhou et al.   Mucosal Immunology

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells

(2017) Michel Enamorado et al.   Nature Communications

Induction of resident memory T cells enhances the efficacy of cancer vaccine

(2017) Mevyn Nizard et al.   Nature Communications

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

(2016) Peter Ellmark et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy

(2016) Alfonso R. Sanchez-Paulete et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

(2015) Todd Bartkowiak et al.   Frontiers in Oncology

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Cutting Edge: Resident Memory CD8 T Cells Occupy Frontline Niches in Secondary Lymphoid Organs

(2014) J. M. Schenkel et al.   JOURNAL OF IMMUNOLOGY

Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden

(2014) Francesca Scrimieri et al.   OncoImmunology

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

(2013) L. C. Sandin et al.   Cancer Immunology Research

Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity

(2013) Henning Lauterbach et al.   Frontiers in Immunology

Subcapsular sinus macrophages promote NK cell accumulation and activation in response to lymph-borne viral particles

(2012) Z. Garcia et al.   BLOOD

Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion

(2012) Dimitra Peppa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

(2012) Asís Palazón et al.   Cancer Discovery

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity

(2011) P. A. Lang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1

(2010) B Huang et al.   GENE THERAPY

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice

(2010) Henning Lauterbach et al.   PLoS One

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

(2009) Chao Wang et al.   IMMUNOLOGICAL REVIEWS

Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain

(2009) Mark Suter et al.   VACCINE

Interleukin-15/Interleukin-15R  Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells

(2008) M. Epardaud et al.   CANCER RESEARCH

Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection

(2008) Christofer Samuelsson et al.   JOURNAL OF CLINICAL INVESTIGATION

Vaccinia Virus-Mediated Inhibition of Type I Interferon Responses Is a Multifactorial Process Involving the Soluble Type I Interferon Receptor B18 and Intracellular Components

(2008) Z. Waibler et al.   JOURNAL OF VIROLOGY

Age-dependent tolerance to an endogenous tumor-associated antigen

(2008) Jennifer A. McWilliams et al.   VACCINE